Home About History History Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree Apr. 2005 Astellas Pharma Inc. (Astellas) was established by merging the former Yamanouchi Pharmaceutical Co., Ltd. and the former Fujisawa Pharmaceutical Co., Ltd. Apr. 2006 Astellas sold Zephama, operating in the over-the-counter drug business, to Daiichi Sankyo Co., Ltd. in Japan to concentrate Astellas' managerial resources on its ethical drug business. Oct. 2007 Astellas launched Geninax®, an oral new-type quinololone antibacterial agent, in Japan. Dec. 2007 Astellas acquired Agensys, Inc., a biotechnology company specialized in therapeutic antibody research and development in cancer in the U.S. June 2010 Astellas acquired OSI Pharmaceuticals, Inc., a biotechnology company in the U.S. to create an oncology platform. July 2011 Astellas launched Betanis® in Japan for the treatment of overactive bladder (OAB). Nov. 2011 Astellas signed United Nations Global Compact. Mar. 2012 Astellas launched a wind turbine power generation station and a woodchip biomass boiler in the Kerry Plant in Ireland. July 2012 Astellas participated in the new public-private partnership to develop a treatment for schistosomiasis-infected preschool children. Sept. 2012 Astellas launched XTANDI® in the U.S. for the treatment of metastatic castration-resistant prostate cancer. Oct. 2012 Astellas launched Gonax® in Japan for the treatment of prostate cancer. Oct. 2012 Astellas entered collaborative new drug discovery research with the National Institute of Advanced Industrial Science and Technology (AIST) for neglected tropical diseases caused by protozoan parasites. Oct. 2012 Astellas launched MYRBETRIQ® in the U.S. for the treatment of OAB. Mar. 2013 Astellas and UCB Japan launched Cimzia® in Japan for the treatment of adult patients with rheumatoid arthritis. Apr. 2013 Astellas announced participation in Global Health Innovative Technology Fund (GHIT Fund). May 2013 Astellas and Amgen concluded an agreement for established alliance innovative joint venture, Astellas Amgen Biopharma in Japan. Apr. 2014 Astellas launched Suglat® in Japan for the treatment of type 2 diabetes. May 2014 Astellas funded a €1.5 million groundbreaking programme to tackle obstetric fistula in Kenya. May 2014 Astellas launched XTANDI® in Japan for the treatment of prostate cancer. Feb. 2016 Astellas acquired Ocata Therapeutics, Inc., a biotechnology company in the U.S. to enable Astellas to establish a presence in ophthalmology and a leading position in cell theapy. Apr. 2016 Astellas launched Repatha® in Japan for the treatment of high cholesterol. Oct. 2016 Astellas and World Anti-Doping Agency announced global initiative to prevent misuse and abuse of medicines for doping in sports. Dec. 2016 Astellas acquired Ganymed Pharmaceticals AG, a biopharmaceutical company, in Germany to further expand Astellas' oncology presence by adding anti-body program, zolbetuximab. Jan. 2017 Astellas participated in Access Accelerated, a global initiative aimed at improving access to non-communicable diseases prevention, diagonosis and treatment. Mar. 2017 Astellas launched LINZESS® in Japan for the treatment of irritable bowel syndrome with conspitation. May 2017 Astellas acquired Ogeda SA, a drug discovery company, in Belgium to expand Astellas' pipeline by adding a selective NK3 receptor atagonist, fezolinetant. Oct. 2017 Astellas entered into a new collaborative research agreement with TB Alliance to discover anti-tuberculosis drugs. Oct. 2017 Astellas entered into a screening collaboration agreement with Medicines for Malaria Venbure to discover antimalarial drugs. Jan. 2018 Astellas acquired Mitobridge, Inc., a bio-venture company in the U.S. to accelerate Astellas' research and development in diseases associated with mitochondrial dysfunctions. Feb. 2018 Astellas acquired Universal Cells, Inc., a bio-venture company which has ability to produce pluripotent stem cells that have lower immunological rejections. Mar. 2018 Astellas participated in Neglected Tropical Diseases Drug Discovery Booster Consortium with DNDi and Seven Other Pharmaceutical Companies. Aug. 2018 Astellas acquired Quethera, a gene theraphy company in the U.K. to further Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma. Sept. 2018 Astellas launched Dafclir® in Japan for the treatment of infectious enteritis caused by Clostridium difficile. Oct. 2018 Astellas and BANDAI NAMCO Entertainment Inc. concluded an agreement for joint development of application for smartphone exercise support application. Nov. 2018 Science Based Targets Initiative approved Astellas’ greenhouse gas reduction plan. Nov. 2018 Astellas launched BLINCYTO® in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Nov. 2018 Astellas launched the Astellas Global Health Foundation to support improving access to health for underserved populations. Dec. 2018 Astellas launched XOSPATA® in Japan and the U.S. to provide a therapeutic option for the treatment of Acute Myeloid Leukemia. Dec. 2018 Astellas acquired Potenza Therapeutics Inc. in the U.S. to add clinical stage novel immuno-oncology programs to Astellas' oncology pipeline. Mar. 2019 Astellas launched EVENITY® in Japan for the treatment of osteoporosis. July 2019 Astellas launched Smyraf® in Japan for the treatment of rheumatoid arthritis in patients. Nov. 2019 Astellas launched Evrenzo® in Japan for the treatment of renal anemia in patients on dialysis. Nov. 2019 Astellas entered into strategic alliance for digital therapeutics with Welldoc, Inc., a digital health company. Dec. 2019 Astellas acquired Xyphos Biosciences, Inc., a biotechnology company in the U.S. to accelerate next-generation cancer immunotherapy. Dec. 2019 Astellas lauched PADCEV® in the U.S. for the treatment of urothelial cancer. Jan. 2020 Astellas acquired Audentes Therapeutics, Inc., a biotechnology company in the U.S. to complement capabilities and resources of Astellas for creating an industry-leading gene therapy company. Apr. 2020 Astellas acquired Nanna Therapeutics Limited, in the U.K. to accelerate Astellas' research in diseases associated with mitochondrial dysfunctions. June 2020 Astellas, City of Yokohama, and Yokohama City University developed science-based exercise programs through industry-government-academia collaboration. Sept. 2020 Astellas launched science-based fitness service, Fit-eNce®. Oct. 2020 Astellas acquired iota Biosciences, Inc. in the U.S. to explore new biosensing and treatment measures using ultra-small implantable medical devices. Dec. 2020 Astellas supported recommendations of Task Force on Climate-related Financial Disclosures (TCFD). Icon Description： Launch of New Products Building a Platform to Support Growth Optimization of Resource Allocation Initiatives to Support Society and Company's Sustainable Growth Rx+® Business ABOUT From the CEO Philosophy VISION Corporate Information Main Products Global Network History Board of Directors Top Management Corporate Governance Policies & Position Statements Ethics & Compliance Medical Care & Pharmaceutical Information Bottom footer menu SITE MAP PRIVACY POLICY ACCESSIBILITY TERMS OF USE CONTACT US DISASTER INFORMATION FOR EMPLOYEES © Astellas Pharma Inc.